Company intelligence / Profile preview

Manhattan Pharmaceuticals, Inc.

New York, New York, United Statesmanhattanpharma.com ↗

Ownership: Private
Development stage: Other

Overview

Manhattan Pharmaceuticals focused on developing and commercializing specialty healthcare products for underserved patient populations. Its portfolio included Hedrin™ for head lice treatment, AST726 for vitamin B12 deficiency via nasal delivery, AST915 for essential tremor as an oral therapy, and a topical gel for mild psoriasis. The company had not received regulatory approval or generated commercial revenue from any product prior to its merger activities and eventual rebranding as TG Therapeutics.

Therapeutic areas: HematologyDermatologyNeurologyInfectious Diseases
Modalities: Small moleculesTopical gels/medical devices
Industry: Biotech

Drug pipeline

2 assets

AST-726

1 more asset in the full pipeline.

Partnerships

Thornton & Ross Ltd.Kerris S.A.

Beyond the preview

Go deeper on Manhattan Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Manhattan Pharmaceuticals, Inc..